Rituximab in pediatric rheumatic diseases: 2 years follow up for immunological long-term effects using a standardized screening and safety protocol.
- Conditions
- M08.0M32.1Juvenile rheumatoid arthritisSystemic lupus erythematosus with organ or system involvement
- Registration Number
- DRKS00020514
- Lead Sponsor
- (Non-profit) Verein: Hilfe für das rheumakranke Kind e.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Severe and/or refractory pediatric rheumatic diseases based on antobody-mediated pathogenesis.
Exclusion Criteria
Acute and severe infection. Primary immunodeficiency.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term immunological effects of Rituximab on B-cell subsets in pediatric systemic lupus erythematosus with organ involvement?
How does Rituximab's efficacy in juvenile rheumatoid arthritis compare to standard-of-care biologics like methotrexate or TNF inhibitors?
Which biomarkers correlate with sustained clinical remission in pediatric rheumatic diseases treated with Rituximab over 2 years?
What adverse events are most frequently observed in DRKS00020514 during 2-year follow-up of Rituximab-treated pediatric patients?
Are there synergistic combination therapies involving Rituximab and B-cell targeting agents for refractory pediatric rheumatic conditions?